RARE – Ultragenyx Pharmaceutical Inc.
Float Short %
9.28
Margin Of Safety %
Put/Call OI Ratio
0.43
EPS Next Q Diff
0.06
EPS Last/This Y
1.23
EPS This/Next Y
1.35
Price
30.29
Target Price
86.05
Analyst Recom
1.19
Performance Q
-22.86
Relative Volume
0.71
Beta
0.21
Ticker: RARE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | RARE | 29.69 | 0.56 | 0.40 | 81543 |
| 2025-08-18 | RARE | 29.69 | 0.47 | 0.42 | 44908 |
| 2025-08-19 | RARE | 29.13 | 0.48 | 0.32 | 45136 |
| 2025-08-20 | RARE | 29.36 | 0.48 | 0.29 | 45172 |
| 2025-08-21 | RARE | 29.6 | 0.47 | 0.03 | 45215 |
| 2025-08-22 | RARE | 29.77 | 0.46 | 0.07 | 45920 |
| 2025-08-25 | RARE | 29.27 | 0.46 | 0.08 | 45883 |
| 2025-08-26 | RARE | 29.55 | 0.46 | 0.02 | 46300 |
| 2025-08-27 | RARE | 30.08 | 0.45 | 0.01 | 47041 |
| 2025-08-28 | RARE | 30.29 | 0.43 | 0.51 | 48117 |
| 2025-08-29 | RARE | 29.96 | 0.43 | 1.36 | 48120 |
| 2025-09-02 | RARE | 32.04 | 0.43 | 0.32 | 48181 |
| 2025-09-03 | RARE | 31.47 | 0.43 | 0.56 | 48967 |
| 2025-09-04 | RARE | 31.28 | 0.44 | 0.41 | 49223 |
| 2025-09-05 | RARE | 31.8 | 0.44 | 0.63 | 49609 |
| 2025-09-08 | RARE | 31.52 | 0.44 | 0.17 | 49676 |
| 2025-09-09 | RARE | 31.51 | 0.44 | 0.23 | 50254 |
| 2025-09-10 | RARE | 31.3 | 0.44 | 0.12 | 50313 |
| 2025-09-11 | RARE | 31.31 | 0.43 | 0.70 | 50639 |
| 2025-09-12 | RARE | 30.29 | 0.43 | 0.31 | 50664 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | RARE | 29.69 | 13.6 | -38.5 | -5.06 |
| 2025-08-18 | RARE | 29.70 | 13.6 | -24.9 | -5.06 |
| 2025-08-19 | RARE | 29.12 | 13.6 | -13.3 | -5.06 |
| 2025-08-20 | RARE | 29.34 | 13.6 | -29.2 | -5.06 |
| 2025-08-21 | RARE | 29.52 | 13.6 | -27.9 | -5.06 |
| 2025-08-22 | RARE | 29.79 | 13.6 | -30.0 | -5.06 |
| 2025-08-25 | RARE | 29.27 | 13.6 | -14.7 | -5.06 |
| 2025-08-26 | RARE | 29.56 | 13.6 | -30.4 | -5.06 |
| 2025-08-27 | RARE | 30.06 | 13.6 | -34.6 | -5.06 |
| 2025-08-28 | RARE | 30.30 | 13.6 | -28.9 | -5.06 |
| 2025-08-29 | RARE | 29.94 | 13.6 | -17.8 | -5.06 |
| 2025-09-02 | RARE | 32.03 | 13.6 | -65.1 | -5.06 |
| 2025-09-03 | RARE | 31.55 | 13.6 | -82.1 | -5.06 |
| 2025-09-04 | RARE | 31.29 | 13.6 | -86.6 | -5.06 |
| 2025-09-05 | RARE | 31.82 | 13.6 | -103.4 | -5.06 |
| 2025-09-08 | RARE | 31.51 | 13.6 | -85.6 | -5.06 |
| 2025-09-09 | RARE | 31.50 | 13.6 | -91.4 | -5.06 |
| 2025-09-10 | RARE | 31.31 | 13.6 | -88.0 | -5.06 |
| 2025-09-11 | RARE | 31.23 | 13.6 | -90.8 | -5.06 |
| 2025-09-12 | RARE | 30.29 | 13.6 | -72.2 | -5.06 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | RARE | -2.51 | 3.23 | 8.49 |
| 2025-08-18 | RARE | -2.51 | 5.22 | 8.52 |
| 2025-08-19 | RARE | -2.39 | 5.22 | 8.52 |
| 2025-08-20 | RARE | -2.39 | 5.22 | 8.52 |
| 2025-08-21 | RARE | -2.39 | 5.22 | 8.52 |
| 2025-08-22 | RARE | -2.39 | 5.22 | 8.52 |
| 2025-08-25 | RARE | -2.39 | 4.78 | 8.52 |
| 2025-08-26 | RARE | -2.39 | 4.78 | 8.52 |
| 2025-08-27 | RARE | -2.39 | 4.78 | 9.38 |
| 2025-08-28 | RARE | -2.39 | 4.78 | 9.38 |
| 2025-08-29 | RARE | -2.39 | 4.78 | 9.38 |
| 2025-09-02 | RARE | -2.39 | 4.77 | 9.38 |
| 2025-09-03 | RARE | -2.39 | 4.77 | 9.38 |
| 2025-09-04 | RARE | -2.34 | 4.77 | 9.38 |
| 2025-09-05 | RARE | -0.07 | 4.77 | 9.38 |
| 2025-09-08 | RARE | -0.07 | 4.79 | 9.38 |
| 2025-09-09 | RARE | -0.07 | 4.79 | 9.38 |
| 2025-09-10 | RARE | -0.07 | 4.79 | 9.38 |
| 2025-09-11 | RARE | -0.05 | 4.79 | 9.28 |
| 2025-09-12 | RARE | -0.08 | 4.79 | 9.28 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.17
Avg. EPS Est. Current Quarter
-1.21
Avg. EPS Est. Next Quarter
-1.11
Insider Transactions
-0.08
Institutional Transactions
4.79
Beta
0.21
Average Sales Estimate Current Quarter
167
Average Sales Estimate Next Quarter
183
Fair Value
Quality Score
37
Growth Score
51
Sentiment Score
34
Actual DrawDown %
83.1
Max Drawdown 5-Year %
-85.2
Target Price
86.05
P/E
Forward P/E
PEG
P/S
4.79
P/B
19.27
P/Free Cash Flow
EPS
-5.53
Average EPS Est. Cur. Y
-5.06
EPS Next Y. (Est.)
-3.71
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-87.34
Relative Volume
0.71
Return on Equity vs Sector %
-377.1
Return on Equity vs Industry %
-364
EPS 1 7Days Diff
EPS 1 30Days Diff
0.17
EBIT Estimation
-72.2
Ultragenyx Pharmaceutical Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1294
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today
news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance
stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market
stock prices RARE premarket after hours
ticker RARE fair value insiders trading